MetaCap

Structure Therapeutics (GPCR) vs Kardigan (KARD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Structure Therapeutics is the larger company by market cap ($1.15 billion vs $1.08 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GPCR-63.76%KARD-47.55%
+32%-18%-68%
Jun 18, 20261 yearNov 20, 2026
GPCR-63.76%KARD-47.55%
+27%-21%-68%
Jun 15, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GPCR versus KARD key metrics
MetricGPCRKARD
Share price$16.13$11.54
Market cap$1.15B$1.08B
1-day change-5.78%-7.83%
YTD return-76.81%—
1-year return-53.00%—
EPS (TTM)$-3.90$-6.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-141.20M—
52-week high$94.90$27.00
52-week low$16.06$11.49
Distance from 52-week high-83.00%-57.26%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+550.09%+255.29%
Average volume1.18M625.83K
Shares outstanding71.59M93.60M
Employees281241
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Structure Therapeutics

GPCR stock →

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees

About Kardigan

KARD stock →

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees

GPCR vs KARD FAQ

Which is bigger, Structure Therapeutics or Kardigan?

Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.15B compared with $1.08B for Kardigan (KARD).

Are Structure Therapeutics and Kardigan in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons